García-Vázquez Rocío, Battisti Umberto Maria, Herth Matthias M
Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark.
Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.
Pharmaceuticals (Basel). 2022 May 30;15(6):685. doi: 10.3390/ph15060685.
Tetrazine ligation has gained interest as a bio-orthogonal chemistry tool within the last decade. In nuclear medicine, tetrazine ligation is currently being explored for pretargeted approaches, which have the potential to revolutionize state-of-the-art theranostic strategies. Pretargeting has been shown to increase target-to-background ratios for radiopharmaceuticals based on nanomedicines, especially within early timeframes. This allows the use of radionuclides with short half-lives which are more suited for clinical applications. Pretargeting bears the potential to increase the therapeutic dose delivered to the target as well as reduce the respective dose to healthy tissue. Combined with the possibility to be applied for diagnostic imaging, pretargeting could be optimal for theranostic approaches. In this review, we highlight efforts that have been made to radiolabel tetrazines with an emphasis on imaging.
在过去十年中,四嗪连接作为一种生物正交化学工具受到了关注。在核医学领域,目前正在探索将四嗪连接用于预靶向方法,这种方法有可能彻底改变最先进的诊疗策略。预靶向已被证明可以提高基于纳米药物的放射性药物的靶本比,尤其是在早期阶段。这使得可以使用半衰期短的放射性核素,而这些核素更适合临床应用。预靶向有可能增加输送到靶标的治疗剂量,并减少对健康组织的相应剂量。结合用于诊断成像的可能性,预靶向对于诊疗方法可能是最佳的。在这篇综述中,我们重点介绍了在四嗪放射性标记方面所做的工作,尤其侧重于成像方面。